Guangxi Visual Technology Co., Ltd., located in Fanchenggang International Medical Open Pilot Zone, Guangxi Province, is a strategic subsidiary of Guangdong Shilian Medical Co., Ltd. The two companies collaborate closely on original, cutting-edge medical imaging technology. Zhenxiangtang's main products are "a series of practical disposable wireless data transmission electronic endoscopes," which also includes "wireless data transmission imaging consumables that are not related to traditional forms of endoscopes." The company's core technology is "practical wireless data transmission technology for medical endoscopes." In addition, the company is also engaged in the research and development of two key technologies: disposable lens (imaging consumables) assembly technology" and "AI-assisted core equipment intelligentization technology." The goal is to realize the “wireless/consumable/intelligent” nature of medical electronic endoscopes, enabling clinicians to operate endoscopes without cables, thereby improving the efficiency of endoscopic diagnosis and treatment in clinical practice. Zhenxiangtang also has a “medical active equipment production license” and a “medical disposable sterile product production license.” The designed production capacity of the equipment is 30,000 sets per year, and the designed production capacity of disposable lenses (imaging consumables) is 6 million pieces (sets) per year. ZKYH AIMED Technology (Guangxi) Co., Ltd. is a wholly-owned subsidiary of Zhongke Yihe Group, handling production registration and overseeing international import and export operations. Zhongke Yihe Group is a high-tech innovative enterprise focusing on clinical medicine, artificial intelligence (AI), and intelligent manufacturing. In 2023, the group relocated its headquarters to Foshan City, Guangdong Province, and established an R&D and sales center in Beijing. After setting up a production registration and import-export center in Guangxi Province in 2024, it officially launched a dual-headquarters strategy with Guangdong and Guangxi as production and registration centers, and Beijing as the R&D and marketing hub.Currently, the company's business and product solutions are fully concentrated on the screening and diagnosis of reproductive and genetic diseases. Through scientific research collaborations with institutions such as Peking University Third Hospital, the Institute of Computing Technology of the Chinese Academy of Sciences (CAS), the Xi'an Institute of Optics and Precision Mechanics of CAS, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, the Second Affiliated Hospital of Xiamen Medical College, and the Second Affiliated Hospital of Soochow University, the company has successfully transformed its research outcomes and continuously invests in R&D to upgrade the "AI-powered chromosome screening technology", which has won three core patents, with the academician team at Peking University Third Hospital as the primary inventor and the "chromosome aberration analysis and micronucleus analysis technology" of multi-center scientific research institutions, including Guangdong Province Hospital for Occupational Disease Prevention and Treatment, the Second Affiliated Hospital of Xiamen Medical College, and the Second Affiliated Hospital of Soochow University. The technologies have been industrialized and applied in the market.Zhongke Yihe has always adhered to the product R&D and innovation concept "From The Doctor, By The Doctor, For The Doctor", taking solving clinical pain points as the driving force for enterprise development. It has established clinical-medical research cooperation as the core strategic pivot for innovation and sustainable development. Committed to providing medical institutions and clinical experts with a "secure, accurate, user-friendly" one-stop platform-based full-chain AI-assisted diagnostic solution, it has long been dedicated to preventing birth defects and enhancing prenatal and postnatal care and population health in China.